How esketamine influences inflammatory cytokines, cortisol and anhedonia in TRD patients is an open question.
Saved in:
| Title: | How esketamine influences inflammatory cytokines, cortisol and anhedonia in TRD patients is an open question. |
|---|---|
| Authors: | Leite, Thalles Rodrigues Alves (AUTHOR), Leitão, Déborah Araújo (AUTHOR), Martins, Letícia Braga (AUTHOR), Bisol, Luísa Weber (AUTHOR) |
| Source: | European Archives of Psychiatry & Clinical Neuroscience. Aug2025, Vol. 275 Issue 5, p1527-1529. 3p. |
| Subjects: | Cytokines, Biomarkers, Antidepressants, Anhedonia, Mental depression, Glucocorticoids, Comorbidity, Drug therapy |
| Abstract: | The article discusses the significance of biomarkers in understanding mental disorders, particularly in relation to treatment-resistant depression and the use of esketamine. It critiques a study for methodological shortcomings, including the use of the Hamilton Depression Rating Scale-24 instead of the more recognized Hamilton Depression Rating Scale-17, and highlights the need for more detailed demographic data, such as body mass index (BMI) and comorbidities, which could influence cortisol and inflammatory biomarker levels. The authors emphasize the importance of considering individual differences and comorbidities in treatment outcomes to inform personalized interventions. [Extracted from the article] |
| Copyright of European Archives of Psychiatry & Clinical Neuroscience is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | The article discusses the significance of biomarkers in understanding mental disorders, particularly in relation to treatment-resistant depression and the use of esketamine. It critiques a study for methodological shortcomings, including the use of the Hamilton Depression Rating Scale-24 instead of the more recognized Hamilton Depression Rating Scale-17, and highlights the need for more detailed demographic data, such as body mass index (BMI) and comorbidities, which could influence cortisol and inflammatory biomarker levels. The authors emphasize the importance of considering individual differences and comorbidities in treatment outcomes to inform personalized interventions. [Extracted from the article] |
|---|---|
| ISSN: | 09401334 |
| DOI: | 10.1007/s00406-025-01960-x |
